[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:mature-t-cell-and-nk-cell-non-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":218,"states":219},"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",34,29,[8,16,23,29,36,43,49,55,61,67,73,79,85,91,97,103,109,116,122,128,134,140,146,152,158,164,170,175,181,186,193,199,206,212],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03161223","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:45.196599Z","2026-05-05T02:43:29.583688Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04747236","Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL",[20],"Phase 2","2026-08-26T02:16:29.226604Z","2026-05-05T02:43:29.141366Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06810778","Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)",[12],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:29.052972Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04234048","Phase 1 Trial of ST-001 nanoFenretinide in Relapsed\u002FRefractory T-cell Non-Hodgkin Lymphoma",[33],"Phase 1","2026-08-26T02:18:21.216897Z","2026-05-05T02:43:29.023064Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT06072131","To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL",[40],"Phase 3","2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.181541Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06733441","A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma",[33],"2026-08-03T02:36:50.517616Z","2026-05-05T02:43:27.594078Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT07293403","Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas",[20],"2026-08-26T02:15:28.524219Z","2026-05-05T02:43:27.284314Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT03011814","Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma",[12],"2026-08-26T02:19:13.549512Z","2026-06-17T02:29:30.057758Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06724237","Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy",[40],"2026-08-26T02:18:27.904411Z","2026-05-13T02:55:06.567458Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06137144","AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.",[12],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:28.704937Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07356245","Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma",[20],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:27.624777Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06615050","A Study of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)",[40],"2026-08-26T02:16:04.914942Z","2026-07-05T05:32:16.764159Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07192471","A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma",[33],"2026-08-26T02:17:59.904383Z","2026-07-05T05:32:16.661363Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[33],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.581486Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07283822","Amping up With PemJAK",[20],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:29.349629Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT04068597","Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:29.159659Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":114,"content_modified":115},"NCT03719105","Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia\u002FLymphoma",[113],"Early Phase 1","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.474501Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05996185","Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma",[20],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:28.341848Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT04288726","Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas",[33],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:28.120885Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT07055477","A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)",[33],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:27.673466Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT07082803","TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas",[33],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:27.605782Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT06176690","Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas",[33],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.308921Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT07195916","A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",[33],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:27.041939Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT06926595","Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention",[20],"2026-08-26T02:19:22.562392Z","2026-05-05T02:35:31.707594Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT03964480","Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.",[],"2026-08-26T02:17:00.709807Z","2026-05-13T02:55:06.180384Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.418667Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":95,"content_modified":174},"NCT05978141","A Registry for People With T-cell Lymphoma",[],"2026-05-13T02:55:06.403613Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT03501576","Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma",[],"2026-08-26T02:17:16.126291Z","2026-05-13T02:55:06.171773Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":65,"content_modified":185},"NCT05135351","Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy",[],"2026-05-05T02:35:31.653701Z",{"nct_id":187,"title":188,"phases":189,"status":190,"updated_at":191,"content_modified":192},"NCT07137481","Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies",[20],"NOT_YET_RECRUITING","2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.805067Z",{"nct_id":194,"title":195,"phases":196,"status":190,"updated_at":197,"content_modified":198},"NCT07729397","Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)",[33],"2026-08-26T02:15:31.806698Z","2026-07-30T01:46:14.450615Z",{"nct_id":200,"title":201,"phases":202,"status":203,"updated_at":204,"content_modified":205},"NCT03922724","Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:45:11.273644Z","2026-05-05T02:43:28.670136Z",{"nct_id":207,"title":208,"phases":209,"status":203,"updated_at":210,"content_modified":211},"NCT05346809","Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma",[20],"2026-08-03T03:20:00.985008Z","2026-05-05T02:43:28.117988Z",{"nct_id":213,"title":214,"phases":215,"status":203,"updated_at":216,"content_modified":217},"NCT03690011","Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",[33],"2026-08-03T03:05:09.265674Z","2026-05-05T02:43:27.128098Z",[],[220,224,228,231,235,239,242,246,250,253,257,261,264,267,270,273,276,280,283,286,289,292,295,298],{"state":221,"count":222,"slug":223},"California",16,"california",{"state":225,"count":226,"slug":227},"New York",15,"new-york",{"state":229,"count":226,"slug":230},"Texas","texas",{"state":232,"count":233,"slug":234},"Pennsylvania",11,"pennsylvania",{"state":236,"count":237,"slug":238},"Michigan",8,"michigan",{"state":240,"count":237,"slug":241},"Ohio","ohio",{"state":243,"count":244,"slug":245},"Georgia",7,"georgia",{"state":247,"count":248,"slug":249},"Florida",6,"florida",{"state":251,"count":248,"slug":252},"Missouri","missouri",{"state":254,"count":255,"slug":256},"Colorado",5,"colorado",{"state":258,"count":259,"slug":260},"Maryland",4,"maryland",{"state":262,"count":259,"slug":263},"Massachusetts","massachusetts",{"state":265,"count":259,"slug":266},"Minnesota","minnesota",{"state":268,"count":259,"slug":269},"Nebraska","nebraska",{"state":271,"count":259,"slug":272},"Tennessee","tennessee",{"state":274,"count":259,"slug":275},"Virginia","virginia",{"state":277,"count":278,"slug":279},"Arizona",3,"arizona",{"state":281,"count":278,"slug":282},"Connecticut","connecticut",{"state":284,"count":278,"slug":285},"Illinois","illinois",{"state":287,"count":278,"slug":288},"Indiana","indiana",{"state":290,"count":278,"slug":291},"New Jersey","new-jersey",{"state":293,"count":278,"slug":294},"North Carolina","north-carolina",{"state":296,"count":278,"slug":297},"Oregon","oregon",{"state":299,"count":278,"slug":300},"Wisconsin","wisconsin"]